Effect of diabetes on short-term mortality and incidence of first hospitalizations for cardiovascular events after recovery from SARS-CoV-2 infection

Diabetes Res Clin Pract. 2022 May:187:109872. doi: 10.1016/j.diabres.2022.109872. Epub 2022 Apr 13.

Abstract

Aim: To evaluate the impact of diabetes and COVID-19 on all-cause-mortality and first hospitalizations for cardiovascular events (CVE): myocardial infarction or stroke, within six months after being tested positive and having recovered from SARS-CoV-2 infection.

Methods: Resident population in Tuscany, Italy of age 45-94 yr without prior hospitalization for CVE, tested positive for SARS-CoV-2 by March 1st, 2020 and afterwards recovering from COVID-19 was compared with age, gender and diabetes matched controls without infection, for incidence rate ratio (IRR) of all-cause-deaths or first CVE at six months follow up.

Results: 46,152 subjects of whom 4,597 with diabetes, tested positive and recovered from SARS-CoV-2 were compared with 1:1 age, gender and diabetes matched controls without infection. COVID-19 was associated with higher all-cause-mortality: IRR:1.92(95 %CI:1.63-2.25) while diabetes with increased risk of first CVE hospitalizations: IRR:2.24(2.18-4.25). Co-presence of COVID-19 and diabetes didn't add any additional excess risk. Being women and statins' use significantly reduced death risk.

Conclusions: After recovery from COVID-19, independently of diabetes, all-cause-mortality risk at six months was twofold increased, while risk of first CVE hospitalization remained unmodified. Diabetes, independently of prior COVID-19, resulted in higher six-months risk of first CVE not of death. Female gender and statins' use reduced both excess risks.

Keywords: All-cause mortality; COVID-19; Cardiovascular events; Diabetes; Gender; Statins.

MeSH terms

  • Aged
  • Aged, 80 and over
  • COVID-19* / epidemiology
  • Diabetes Mellitus* / epidemiology
  • Female
  • Hospitalization
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors*
  • Incidence
  • Male
  • Middle Aged
  • Myocardial Infarction*
  • SARS-CoV-2

Substances

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors